SCHEMBL2066286

SCHEMBL2066286

O=C1NC(=S)SC1=Cc1cccc(OCc2c(F)cccc2Cl)c1OCc1c(F)cccc1Cl

nearest known ligand 0.73

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
PTP4A3 O75365 9/20 0.73
PIM1 P11309 2/20 0.54
PDE4B Q07343 1/20 0.53
GSK3B P49841 1/20 0.53
CISD1 Q9NZ45 1/20 0.50
NAT1 P18440 1/20 0.48
KCNH2 Q12809 1/20 0.47
HPGD P15428 1/20 0.45
CRHBP P24387 1/20 0.44
CRHR2 Q13324 1/20 0.44
GSK3A P49840 1/20 0.44
CTSD P07339 1/20 0.44
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10090223 1.00 PTP4A3 (0.73) PTP4A3PIM1PDE4BGSK3BCISD1
SCHEMBL2066284 1.00 PTP4A3 (0.73) PTP4A3PIM1PDE4BGSK3BCISD1
SCHEMBL2065201 0.85 PTP4A3 (0.81) PTP4A3PIM1GSK3BCISD1
SCHEMBL2065204 0.85 PTP4A3 (0.81) PTP4A3PIM1GSK3BCISD1
SCHEMBL10090197 0.85 PTP4A3 (0.77) PTP4A3PIM1GSK3BCISD1
SCHEMBL2066247 0.85 PTP4A3 (0.77) PTP4A3PIM1GSK3BCISD1
SCHEMBL2066245 0.85 PTP4A3 (0.77) PTP4A3PIM1GSK3BCISD1
SCHEMBL10090212 0.85 PTP4A3 (1.00) PTP4A3PIM1GSK3BCISD1KCNH2
SCHEMBL2066444 0.81 PTP4A3 (0.71) PTP4A3PIM1PDE4BGSK3BCISD1
SCHEMBL2066441 0.81 PTP4A3 (0.71) PTP4A3PIM1PDE4BGSK3BCISD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148541-B2 Rhodanine derivatives, a process for the preparation thereof and pharmaceutical composition containing the same KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2012-04-03 US claimed
US-20090042872-A1 Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2009-02-12 US claimed
US-8148541-B2 Rhodanine derivatives, a process for the preparation thereof and pharmaceutical composition containing the same KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2012-04-03 US disclosed
US-20090042872-A1 Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042872-A1 Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same PTPRR, PTPRG, PTPRS PTP4A3 28/4885PIM1 2536/4885PDE4B 720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.